Neoplasms

Symptoms and General Pathology

All Conditions

Blood and Lymph Conditions

Diseases and Abnormalities at or Before Birth

Rare Diseases

Neoplasm Metastasis

Thalassemia

beta-Thalassemia

Hepatoblastoma

Anemia

Hemolysis

Anemia, Hemolytic

Anemia, Hemolytic, Congenital

Hematologic Diseases

Hemoglobinopathies

Genetic Diseases, Inborn

Neoplasms by Histologic Type

Beta-thalassemia

Central Nervous System Depressants

All Drugs and Chemicals

Platelet Aggregation Inhibitors

Anticonvulsants

Anesthetics

Rocuronium

Propofol

Sevoflurane

Bromides

Children 0-2 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV

Children 2-18 years old with oncological diseases who need an MRI under general anesthesia, will receive sugammadex 2mg/kg IV

Introductory anesthesia: sevoflurane up to 8 rev /% + Air + O2 or propofol 1% 2 mg / kg intravenously.

Maintenance: sevoflurane up to 3 rev /% + Air + O2, introduction of rocuronium bromide in a dose of 0.4 mg / kg, intravenously, as a bolus injection.

At the end of anesthesia: sugammadex in a dose of 2 mg / kg, intravenously, as a bolus injection

Sugammadex

Marina Tikhonova, MD

Eugene Pashanov, Prof. PhD

Anna Konstantinova, MD

Sugammadex is a selective antidote to muscle relaxants rocuronium bromide and vecuronium bromide. Sugammadex is a modified gamma-cyclodextrin, a compound that selectively binds rocuronium bromide and vecuronium bromide. It forms a complex with them in the blood plasma, which leads to the decrease in the concentration of muscle relaxant binding to nicotinic receptors in the neuromuscular synapse. The result is the the elimination of neuromuscular blockade caused by rocuronium bromide or vecuronium bromide. Sugammadex is used to eliminate neuromuscular blockade caused by rocuronium bromide in children aged 2 years and adolescents in standard clinical situations. The aim of the study is to prove the efficacy and safety of sugammadex in children under 2 years

Nowadays muscle relaxants are widely used in pediatric practice, but their use is fraught with numerous risks and complications. The main ones are the residual neuromuscular block and the possibility of developing a recurrence in the patient. In connection with this, the development and introduction into practical anesthesiology of new, more effective drugs for arresting the action of muscle relaxants is still relevant.

One of the them, sugammadex was recently introduced into clinical practice and provided a fundamentally new approach to the recovery of neuromuscular conduction. Often, children under two years of age need general anesthesia for MRI (prolonged stay in the device, apnea to get a high-quality image without respiratory artifacts, severe pain syndrome, severe neurological deficit, etc.). The aim of the study is the evaluation of the efficacy of sugammadex, estimated by restoring neuromuscular conduction within 0-120 seconds after bolus administration, and the safety and tolerability of sugammadex in children under two years of age. Children will be observed in the hospital during 24 hours. A group of patients from 2 to 18 years of age, in whom the drug sugammadex is used as standard therapy will be taken as a comparison group .

the Efficacy and Safety of Sugammadex in Children 0-2 Years Old

Efficacy and Safety Study of Sugammadex in Children 0-2 Years Old

De-identified individual participant data for all primary and secondary outcome measures will be made available

The time of the elimination of neuromuscular blockade (in seconds)

Assessment of all adverse events from the time of injection to the time of leaving of the MRI department

Assessment of all adverse events during next 24 hours

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
the Efficacy and Safety of Sugammadex in Children 0-2 Years Old	NCT03728543	Anesthesia Pediatric Cance... Pediatric Tumor Pediatric Hepat... Beta-Thalassemi... Hepatic Metasta...	Sugammadex	- 18 Years	Federal Research Institute of Pediatric Hematology, Oncology and Immunology
the Efficacy and Safety of Sugammadex in Children 0-2 Years Old	NCT03728543	Anesthesia Pediatric Cance... Pediatric Tumor Pediatric Hepat... Beta-Thalassemi... Hepatic Metasta...	Sugammadex	- 18 Years	Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Spots Global Cancer Trial Database for pediatric hepatoblastoma